Research programme: peptide drug conjugates - Ellipses Pharma
Latest Information Update: 06 Oct 2021
At a glance
- Originator Ellipses Pharma
- Class Antineoplastics; Drug conjugates; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Solid tumours
Most Recent Events
- 16 Sep 2021 Preclinical trials in Glioblastoma in United Kingdom, prior to September 2021
- 16 Sep 2021 Preclinical trials in Solid tumours in United Kingdom, prior to September 2021